MedTrace Logo

A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

NCT06895928 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2025-04-22

No results posted yet for this study

Summary

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.

Conditions

Interventions

DRUG

SHR-A2102

SHR-A2102 for injection.

DRUG

Bevacizumab Injection

Bevacizumab injection.

DRUG

Adebelimab Injection

Adebelimab injection.

DRUG

Ametinib Mesylate Tablets

Ametinib mesylate tablets.

DRUG

Osimertinib Mesylate Tablets

Osimertinib mesylate tablets.

Sponsors & Collaborators

  • Shanghai Hengrui Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-28
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06895928 on ClinicalTrials.gov